EUVIMEDEUVIMED entdecken
Crossref

Daraxonrasib: First Approval

Yahiya Y Syed

Drugs · 17.11.2026

DOI: 10.1007/s40265-026-02414-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs, online erschienen am 17.11.2026. Verfasst von Yahiya Y Syed. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Die Arbeit nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daraxonrasib (RASONQUE™) is an oral, multiselective, noncovalent RAS(ON) inhibitor being developed by Revolution Medicines for the treatment of solid tumours, including pancreatic ductal adenocarcinoma (PDAC), non-small-cell lung cancer and colorectal cancer. Daraxonrasib received its first approval in the USA on 26 August 2026 for the treatment of adults with metastatic PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. This article summarizes the milestones in the development of daraxonrasib leading to its first approval for metastatic PDAC.

Autor:innen und Institutionen

  • Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Zitieren

APA

Syed, Y. Y. (2026). Daraxonrasib: First Approval. Drugs. https://doi.org/10.1007/s40265-026-02414-x

Vancouver

Syed YY. Daraxonrasib: First Approval. Drugs. 2026. doi:10.1007/s40265-026-02414-x

BibTeX
@article{Syed2026,
  author = {Syed, Yahiya Y},
  title = {Daraxonrasib: First Approval},
  journal = {Drugs},
  year = {2026},
  doi = {10.1007/s40265-026-02414-x}
}
Kostenlos starten →